In April 2024, Barinthus Bio announced topline results from the Phase 1b/2 APOLLO dose-ranging trial (also known as HPV001) ...

Barinthus Biotherapeutics plc has announced its strategic transformation focusing on immunology and inflammatory diseases, highlighting its promising immunotherapy VTP-1000 for celiac disease ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Reports FY24 revenue $15M, consensus $10M. “We’ve entered 2025 with a refreshed strategic focus on immunological and inflammatory diseases.

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1 ...

José Anderson hits a two-run single to left field to give the Brewers the lead with a score of 4-2 in the top of the 7th ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Edouard Julien hits an opposite field three-run home run to left field in the bottom of the 2nd to give the Twins a 3-0 lead ...

Developer says its plan to run a 265km HVDC cable underground from outer Melbourne would be cheaper, faster, more robust – and friendlier to farmers.

A red tag on the entrance of an apartment building in Ypsilanti has residents saying they have been living in unsafe ...

Release Jan 10 - Barinthus Bio: In a shift to focus on immunology and inflammation indications, the biotech is halting further development of VTP-300 for chronic hepatitis B viral infection and ...